ALLR

0.78509.25%
DD

Daniel Douglas Von Hoff

Member of Scientific Advisory Board

Dr. Daniel Douglas Von Hoff, also known as Dan, MD, FACP, FASCO, FAACR, was Member of International Scientific Advisory Board of HUYA Bioscience International, LLC. He serves as Member of Clinical Advisory Board of Aimed Bio Inc. Dr. Hoff is Member of Scientific Advisory Board of Soley Therapeutics, Inc. Dr. Von Hoff is Member of scientific Advisory Board of Systems Oncology, LLC. He is Clinical Advisory Board of Racura Oncology Ltd (formerly known as Race Oncology Limited) from July 2, 2024. He is Member of Development Advisory Panel of Revitope Oncology, Inc. Dr. Hoff is Member of Scientific Advisory Board of Moleculin Biotech, Inc. from November 2024. He is Member of Scientific/Clinical Advisory Board of EnGeneIC Ltd from October 2024. He is an internationally recognized physician and scientist. A pioneer and world leader in translational medicine, his major interest is in the development of new anticancer agents and has been involved in clinical studies. His research at TGEN focuses on the development of therapies for patients with advanced pancreatic cancer. He and his colleagues have contributed to the development of many FDA approved pharmaceuticals, including gemcitabine, irinotecan, capecitabine, nab-paclitaxel and nal-IRI, which are used in the treatment for pancreatic cancer. He was appointed to President Bush's National Cancer Advisory Board in 2004-2010. He was also the past President of the American Association for Cancer Research (the world's largest cancer research organization) and past board member of the American Society of Clinical Oncology. He was the founder of ILEX Oncology, a company that had two anti-cancer agents approved by the FDA and acquired by Genzyme. He was Member of Scientific Advisory Board of Lycia Therapeutics, Inc. until 2026. He was Member of Scientific Advisory Board of Avesta76 Therapeutics Inc. He is Co-Founder and Chief Clinical Strategist and Director at Systems Oncology, LLC. He served as Member of Scientific Advisory Board at Agenus Inc. until October 2023. He serves as Member of Scientific Advisory Board at Immunophotonics, Inc. He serves as Member of Clinical Advisory Board at Compass Therapeutics Inc. since 2022. He was Member of Scientific Advisory Board at Viracta Therapeutics, Inc. until February 2025. He serves as a Member of Scientific Advisory Board at Promontory Therapeutics Inc., Aptose Biosciences Inc., Everist Health Inc., FORMA Therapeutics, Inc., Glyconix Corp., ENDECE, LLC, Astex Pharmaceuticals, Inc., Kirax Corporation, MetronomX, Pte. Ltd., Montigen Pharmaceuticals, Inc., Cantex Pharmaceuticals, Inc., Mirna Therapeutics, Inc., Horizon Discovery Group plc, OncoHoldings, Inc., Theraclone Sciences, Inc., InNexus Biotechnology, Inc., Alethia BioTherapeutics Inc., Cerulean Pharma Inc., MBC Pharma, Inc., Genetics Squared, Inc., SynDevRx, Inc., Amnestix Inc., Five Prime Therapeutics, Inc., Ras Therapeutics, Inc., ImQuest Pharmaceuticals, Inc., Progen Pharmaceuticals, Inc., Light Sciences Oncology, Inc., Erimos Pharmaceuticals, LLC, the National Cancer Institute and Vidacare LLC. He serves as Member of Scientific Advisory Board at Oncolyze, Inc. He has been Chairman of the Scientific Advisory Board of Axis Therapeutics Limited since March 28, 2019. Dr. Von Hoff serves as Member of Scientific Advisory Board at TME Pharma N. V. (formerly known as NOXXON Pharma N. V.) since February 2021. Dr. Von Hoff served as Member of Scientific and Strategic Advisory Board at Helix BioPharma Corp. from March 2018 to November 1, 2018. Dr. Von Hoff Founded Allarity Therapeutics A/S (formerly known as Oncology Venture A/S) and serves as its Member of Scientific Advisory Board. Dr. Von Hoff serves as a Senior Advisor of Clinical Development at Tolero Pharmaceuticals, Inc. Dr. Von Hoff serves as the Chief Scientific Officer of Ascalon International, Inc. and TCRS. He serves as the Chief Scientific Officer of US Oncology at Kalos Therapeutics, Inc. He serves as Clinical Advisor at Kura Oncology, Inc. He is the Co-Founder and Chief Medical Officer of Systems Medicine, Inc. He serves as a Consultant of Oncolytics Biotech Inc. He serves as an Executive Vice President and Physician-In-Chief at The Translational Genomics Research Institute. He serves as a Scientific Advisor of Aqualis ASA. He serves as the Chief Scientific Officer of The Virginia G. Piper Cancer Center/Clinical Research Institute at HonorHealth. He serves as Member of Scientific Advisory Board at Neotx Holdings Ltd. He serves as a Scientific Advisor of MedTrust Online, LLC and Esperance Pharmaceuticals, Inc. He serves as a Consultant of US Business Biotech Relations at AAIOncology. He serves as a Scientific Advisor of Boston Millennia Partners. He served as a Clinical Advisor of BIND Therapeutics, Inc. (now DNIB Unwind, Inc.). He is Scientific Advisor at Erimos Pharmaceuticals, LLC and served as its Clinical Advisor. He serves as Consulting Medical Officer at MetronomX, Pte. Ltd. He serves as the Chief Scientific Officer and Co-Director of Research at US Oncology Inc. He is also Chief Scientific Officer for Scottsdale Healthcare Clinical Research Institute. He serves as a Senior Investigator and Head of Translational Research at Translational Drug Development Division and Head of Pancreatic Cancer Research Program in Phoenix, Arizona. He serves as General Manager of Tennessee Technical Services LLC. He served as an Executive Director of Tissue Banking & Analysis Center Inc. He co-founded Cylene Pharmaceuticals, Inc. in 1998 and served as its Senior Vice President of Medical Affairs. He served as the Chief Development Officer at INSYS Therapeutics, Inc. since January 2011 and also served as its Director of Scientific Development and Consultant since March 2011. He served as Senior Principal Investigator at Niiki Pharma Inc. He served as Senior Vice President of Medical Affairs at Aptose Biosciences Inc., since October 28, 2013. He served as Senior Vice President of Clinical Development at Tolero Pharmaceuticals, Inc. He served as Scientific and Clinical Advisor at Vaccinex, Inc. He served as a Scientific Advisor at Pharmatech Oncology, Inc. He served as a Clinical Consultant of Astex Therapeutics Limited. Dr. Von Hoff co-founded Molecular Profiling Institute, Inc. He holds an appointment as Professor of Medicine, Mayo Clinic. He served as the Chief Executive Officer at CTRC Research since 1995. He served as a Strategic Advisor at Symphony Capital LLC. He served as a Vice President of Clinical Development, Vice President of Medical Affairs, Chief Medical Officer and Head of the Medical/Clinical Affairs at Cylene Pharmaceuticals, Inc. He founded ILEX Oncology Inc. He served as Medical & Scientific Advisor at Mersana Therapeutics, Inc. He served as Director of Clinical Translational Research at the Translational Genomics Research Institute and as a Director of Translational Drug Development Program, Tucson, Arizona, United States. He has been the Chairman of Scientific Advisor

Positions